Advertisement
Screener

EVOLUS, INC. (EOLS) Net Margin

Evolus, Inc. Net Margin

Net margin is the percentage of revenue a company keeps as profit after every expense and tax. It is net income divided by revenue, and the table shows both amounts beside the percentage. A higher net margin means more of each sales dollar reaches the bottom line. One-time gains, write-downs and tax items pass through net income, so a single period's net margin can move for reasons unrelated to the underlying business. Quarterly and annual points each use the amounts filed for that same period, so a single quarter can swing with the seasons.

  • Evolus, Inc. net margin for the quarter ending 2026-06-30 was -9.58%, a change of 15.13% year-over-year.
  • Evolus, Inc. net margin for the quarter ending 2026-03-31 was -14.59%, a change of 12.98% year-over-year.
  • Evolus, Inc. net margin for the quarter ending 2025-12-31 was 0.14%, a change of 8.75% year-over-year.
  • Evolus, Inc. net margin for the quarter ending 2025-09-30 was -22.82%, a change of 8.56% year-over-year.
  • Evolus, Inc. net margin for fiscal 2025 was -17.38%, a change of 1.56% from fiscal 2024.
  • Evolus, Inc. net margin for fiscal 2024 was -18.94%, a change of 11.59% from fiscal 2023.
  • Evolus, Inc. net margin for fiscal 2023 was -30.52%, a change of 19.55% from fiscal 2022.
  • Evolus, Inc. net margin for fiscal 2022 was -50.07%, a change of -3.11% from fiscal 2021.
Available history
2019-06-30 to 2026-06-30
Data captured

Historical Net Margin

DateNet MarginNet incomeRevenue
2026-06-30-9.58%-$8.05M$84.08M
2026-03-31-14.59%-$10.67M$73.14M
2025-12-310.14%$130,000.00$90.3M
2025-09-30-22.82%-$15.74M$68.97M
2025-06-30-24.70%-$17.14M$69.39M
2025-03-31-27.57%-$18.89M$68.52M
2024-12-31-8.60%-$6.79M$78.95M
2024-09-30-31.38%-$19.17M$61.09M
2024-06-30-16.96%-$11.35M$66.91M
2024-03-31-22.09%-$13.11M$59.33M
2023-12-31-19.40%-$11.83M$61M
2023-09-30-33.83%-$16.92M$50.02M
2023-06-30-36.76%-$18.14M$49.35M
2023-03-31-35.45%-$14.79M$41.72M
2022-12-31-30.16%-$13.16M$43.65M
2022-09-30-59.81%-$20.28M$33.9M
2022-06-30-63.16%-$23.47M$37.16M
2022-03-31-51.61%-$17.5M$33.91M
2021-12-31-52.45%-$18.18M$34.66M
2021-09-30-72.85%-$19.43M$26.68M
2021-06-30-59.78%-$15.6M$26.1M
2021-03-3152.29%$6.4M$12.24M
2020-12-31-537.95%-$110.69M$20.58M
2020-09-30-64.88%-$11.46M$17.66M
2020-06-30-270.63%-$21.13M$7.81M
2020-03-31-188.02%-$19.74M$10.5M
2019-12-31-74.60%-$14.51M$19.45M
2019-09-30-204.94%-$26.98M$13.17M
2019-06-30-1625.57%-$37.57M$2.31M

Annual Net Margin

DateNet MarginNet incomeRevenue
2025-12-31-17.38%-$51.64M$297.18M
2024-12-31-18.94%-$50.42M$266.27M
2023-12-31-30.52%-$61.69M$202.09M
2022-12-31-50.07%-$74.41M$148.62M
2021-12-31-46.96%-$46.81M$99.67M
2020-12-31-288.31%-$163.01M$56.54M
2019-12-31-257.79%-$90.03M$34.93M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Altimmune, Inc. (ALT)United States$0.593B-6.43